# Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil

> **NCT07163845** · — · ACTIVE_NOT_RECRUITING · sponsor: **Valneva Austria GmbH** · enrollment: 5354 (actual)

## Conditions studied

- Chikungunya Virus Infection

## Interventions

- **BIOLOGICAL:** Live-attenuated CHIKV vaccine VLA1553

## Key facts

- **NCT ID:** NCT07163845
- **Lead sponsor:** Valneva Austria GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-22
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 5354 (ACTUAL)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07163845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07163845, "Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07163845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*